Marijuana Use Doubles Chances of Future Psychotic Disorders, Study Finds” style=”width:100%;max-height:420px;object-fit:cover;border-radius:8px;display:block;” />#78 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating adolescents should be aware that marijuana use during teenage years significantly increases the risk of developing psychotic disorders in adulthood, which has implications for screening, patient counseling, and early intervention strategies. This evidence strengthens the clinical rationale for discouraging cannabis use in adolescent populations and supports mental health risk assessment conversations during routine care. Understanding this association helps clinicians provide informed guidance to patients and families about long-term psychiatric consequences beyond commonly discussed acute effects.
This longitudinal study found that adolescents who use marijuana have approximately double the risk of developing psychotic disorders in adulthood compared to non-users, with risk appearing dose and frequency dependent. The findings are particularly relevant given the increasing potency of cannabis products and their growing availability to minors in legalized markets. Clinicians should be aware that early cannabis exposure during critical neurodevelopmental periods may confer significant psychiatric vulnerability, especially in patients with genetic predisposition to psychosis. This research supports current evidence-based guidance recommending screening for personal and family psychiatric history before cannabis use in adolescents and young adults. For clinical practice, these results underscore the importance of counseling teenage patients and their families about psychotic risk as part of comprehensive substance use prevention and early intervention strategies.
“What we’re seeing in the literature is a genuine dose and frequency-dependent risk in adolescents whose brains are still developing, and this fundamentally changes how I counsel families who want to consider cannabis therapeutically for their teenagers—the window for safe use in this population is narrower than many realize, and we need to be honest about that vulnerability rather than pretend the risk doesn’t exist.”
💭 This longitudinal study adds to growing evidence that adolescent cannabis use carries meaningful psychiatric risk, particularly regarding psychotic disorders, though clinicians should interpret the findings within important context. The doubling of psychotic disorder risk is concerning and biologically plausible given cannabinoid effects on dopaminergic systems during critical neurodevelopmental periods, yet the absolute baseline risk of psychosis remains relatively low, and the study cannot definitively isolate causation from confounding factors like genetic vulnerability, concurrent substance use, or undiagnosed prodromal symptoms that may have prompted cannabis initiation. When counseling adolescent patients and families, providers should acknowledge this identified risk while avoiding alarmism, recognizing that cannabis use patterns vary widely and that vulnerability to psychotic illness involves multiple genetic and environmental factors beyond cannabis exposure alone. Practically, this evidence strengthens the rationale for including cannabis use screening and psychosis risk discussion in adolescent mental health assessments,
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
